Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].

Bulletin du cancer - 1 Dec 2009

Bibeau F, Frugier H, Denouel A, Sabourin J-C, Boissiere-Michot F

Abstract excerpt

The KRAS status is now a mandatory prerequisite in order to treat metastatic colorectal patients with anti-EGFR (epidermal growth factor receptor) antibodies, such as cetuximab (Erbitux) or panitumumab (Vectibix). KRAS mutations are unambiguously linked to a lack of response to these targeted therapies and to a poor outcome. The optimal determination of the KRAS status should be based on coordination between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Genes, ras

Share to Panitumumab

Share to Pathology, Molecular

Source

Identifiers

PMID: 20034866
DOI: 10.1684/bdc.2009.0993

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].PMID 20034866Read ↗

[Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].Semantic proximity Read ↗

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.Semantic proximity Read ↗

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.Semantic proximity Read ↗

[Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma].Semantic proximity Read ↗

Practical and molecular evaluation of colorectal cancer: new roles for the pathologist in the era of targeted therapy.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.Semantic proximity Read ↗

[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].Semantic proximity Read ↗

Multi-Center Evaluation of the Fully Automated PCR-Based Idylla™ KRAS Mutation Assay for Rapid KRAS Mutation Status Determination on Formalin-Fixed Paraffin-Embedded Tissue of Human Colorectal CancerSemantic proximity Read ↗

KRAS mutations: analytical considerations.Semantic proximity Read ↗

[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].Semantic proximity Read ↗

[Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.